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Prediction of MACE After ACS
Demographics and Angiography Versus Imaging*Pedro R. Moreno, MDNew York, New YorkYesterday is not ours to recover,
but tomorrow is ours to win or to lose
dLyndon B. Johnson (1)
Current prevention of major adverse cardiovas-
cular events (MACE) after acute coronary syn-
dromes (ACS) is based on aggressive medical
therapy, and guideline-driven treatment of tradi-
tional coronary risk factors. These include achieving
low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, blood pressure, and glyco-
sylated hemoglobin target levels, smoking cessation,
and physical activity. In patients with left ventricu-
lar ejection fraction below 40%, the use of an
angiotensin-converting enzyme inhibitor is recom-
mended, and in patients with left ventricular ejection
fraction below 35% an automatic implantable
cardioverter-deﬁbrillator should be considered (2).See page 1263This universal therapeutic approach is based on a
practical concept: All patients after an ACS diag-
nosis must receive aggressive, goal-oriented medical
therapy to reduce recurrent events. If coronary risk
factors are successfully treated, further risk strat-
iﬁcation with biomarkers or novel imaging tech-
nology may not change therapy. In summary, the
current practice of secondary prevention after ACS
is purely based on traditional medicine, and does not*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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Speaker’s Bureau of AstraZeneca.necessarily include additional testing. Nevertheless,
even with second-generation P2Y12 inhibitors,
MACE rates are signiﬁcant, reaching 9% to 14%
during the ﬁrst 12 to 17 months (3,4). Therefore,
clinical practice of secondary prevention after ACS
has a signiﬁcant opportunity for improvement. The
question is how.Identifying Patients at Risk for MACE After ACS
Cardiovascular death, myocardial infarction, and
repeat revascularization after ACS are equally
divided between events related to the culprit lesion
(restenosis, stent thrombosis) and events related to
nonculprit lesions (NCL). Within the ﬁrst group,
drug-eluting stents contributed signiﬁcantly, and
bioabsorbable stents may offer modest advantages
(5). However, there is little room for improvement
in this group. The great opportunity lies in identi-
fying and treating patients with high-risk NCL
responsible for future MACE.
Recently, several intracoronary and noninvasive
imaging studies using multivessel intravascular ul-
trasound (IVUS) with radiofrequency backscattered
analysis or computerized tomography have properly
identiﬁed high-risk, nonculprit, thin-cap ﬁbroa-
theroma (TCFA) responsible for future MACE in
patients with ACS or angina pectoris (6–9). How-
ever, a direct link between clinical data and high-risk
TCFA is missing.
Although recent observational studies suggest that
an aggregate approach using biomarkers for in-
ﬂammation, cell stress, and coagulation may help to
identify patients at increased risk for recurrent events
(10), more traditional approaches including the
GRACE (Global Registry of Acute Coronary
Events), CRUSADE (Can Rapid Risk Stratiﬁcation
of Unstable Angina Patients Suppress Adverse
Outcomes), and TIMI (Thrombolysis In Myocardial
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1274Infarction) scores are commonly used. However,
these scores are derived from demographic factors
that may be ubiquitously distributed in the ACS
population. An aggregate approach, using a combi-
nation of noninvasive biomarkers and invasive im-
aging to predict high-risk plaques, is yet another
possible strategy and was used in a paper in this issue
of iJACC.
The Present Study
In this issue of iJACC, Bourantas et al. (11) evalu-
ated the predictive value of the Framingham risk
score plus angiography to identify patients with
documented high-risk, nonculprit TCFA. Using
the 3 IVUS-derived morphologic predictors of
MACE, this subanalysis of the PROSPECT
(Providing Regional Observations to Study Pre-
dictors of Events in the Coronary Tree) study
compared the Framingham risk score (FRS) in pa-
tients with high-risk ($2 predictors) NCL versus
patients with low risk (#1 predictor). Angiographic
data were also included to improve prediction ac-
curacy. The FRS was borderline higher in the high-
risk group (p ¼ 0.04), in addition to patients with
more extensive coronary artery disease (p ¼ 0.001).
However, the FRS had poor discrimination in
detecting patients containing high-risk TCFA (area
under the curve of 0.55). Adding angiography
slightly improved the area under the curve to 0.64.
The authors concluded that clinical and angio-
graphic characteristics had poor predictive accuracy
in identifying patients with untreated high-risk
plaques responsible for future coronary events. The
absence of a direct link between clinical factors and
the presence of high-risk, nonculprit TCFA
responsible for future MACE underscores the less-
than-optimal risk stratiﬁcation currently used in
clinic practice. It also highlights the unique role
that intracoronary imaging has to properly identify
high-risk, nonculprit TCFA in patients with ACS.
Applying the FRS to Predict High-Risk TCFA
Detected by IVUS in Patients With ACS
Although an attractive concept, a number of reasons
might explain the lack of predictive ability of an
aggregate FRS þ angiographic approach in this
study. It is important to note that the Framingham
criteria may not be appropriate for the kind of
relational analysis in this paper, when dealing in
patients with documented ACS events. Originally
conceived in 1948, at a time when CAD was not
well understood, the FRS has been successivelyimproved to predict long-term cardiovascular risk
(12,13). However, this prediction algorithm was
developed and validated exclusively in patients
without overt cardiovascular disease, and should be
applied only in the setting of primary prevention.
Second, nonculprit-related MACE after ACS
was previously estimated at a rate of 6% to 7% per
year (14,15). However, the PROSPECT study
identiﬁed a much lower event rate, which was close
to 3% to 4% per year (6). This lower event rate, even
though not the primary focus of this study, could
make it difﬁcult to identify clinically relevant, in-
dependent predictors. More importantly, the ma-
jority were “soft events,” including recurrent angina,
hospitalization, and repeat revascularization. The
FRS was not designed to predict soft events in
patients with established cardiovascular disease, af-
ter ACS. Furthermore, even if it did correlate to
high-risk plaque, one cannot be sure what would be
the value of FRS predicting high-risk plaque if it did
not reliably predict events in this population. Even
in the original PROSPECT dataset, TCFA
morphology by itself was associated with few events.
It was necessary to add 2 additional predictors,
including plaque burden and minimal luminal area,
to achieve clinical relevance. Plaques with $2 pre-
dictors had between 4% to 6% MACE per year (6).
In addition, the incidence of this “high-risk TCFA”
(16) was present in only 4.6% of the population, as
previously reported in the Motoyama et al. study
(9). Therefore, applying a marker of hard events
such as FRS would not perform well if the pre-
dominant event of interest was anatomic, or is not
very common, and even if clinical, is a soft one, such
as rehospitalization for ACS or revascularization.
The PROSPECT study established the natural
history of high-risk, nonobstructive TCFA. How-
ever, it was not designed to test the role of optimal
medical therapy in reducing events. It is possible
that a very aggressive pharmacological protocol
guided towards plaque regression may have obtained
even lower event rates. In fact, current studies
conducted to evaluate the role of lifestyle modiﬁ-
cations and aggressive medical therapy documented
signiﬁcant reductions in MACE after ACS (17),
suggesting a consistent response at the plaque level.
Susceptibility of High-Risk TCFA
to Plaque Regression
Novel coronary imaging, not only contributed to
identify the incidence, morphological predictors,
and the natural history of high-risk TCFA,
but also documented consistent changes in plaque
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1275composition after aggressive statin therapy. Pivotal,
sequential, noninvasive studies evaluating high-risk,
low-attenuated plaques documented signiﬁcant re-
ductions in plaque volume after 1 year of aggressive
statin therapy (18). Simultaneously, IVUS virtual
histology studies documented a 75% conversion from
TCFA to thick-cap ﬁbroatheroma after 1 year of
therapy (19). Optical coherence tomography studies
complemented these ﬁndings, with improvements of
ﬁbrous cap thickness after pitavastatin therapy (20).
More recently, the YELLOW (Reduction in Yellow
Plaque by Aggressive Lipid-Lowering Therapy) trial
identiﬁed patients with lipid-rich, nonculprit pla-
ques, using near-infrared spectroscopy. Lipid con-
tent, as quantiﬁed by lipid core burden index, showed
signiﬁcant reduction in patients randomized to 40
mg of rosuvastatin after 7 weeks of therapy (21).
Therefore, high-risk TCFA is highly responsive to
aggressive medical therapy. However, medical ther-
apy must be appropriately given, and changes in lipid
proﬁle must be documented as improvements in the
demographic proﬁle.
Documentation of high-risk, nonculprit lesions is
only relevant if they lead to recurrent events. These
events occur mainly because of lack of aggressiveness
in secondary prevention, or TCFA refractoriness to
medical therapy. Extensive neovascularization,
intraplaque hemorrhage, and rapid expansion may
play a role in refractoriness, leading to recurrent
events. However, this is the exception and not the
rule. The majority of ruptured plaques will heal
without consequences. Furthermore, optimal medi-
cal therapy has proven to stabilize plaques and reduce
events. In this study, baseline demographic pre-
dictors at the time of intervention failed to establish
a link between clinical factors and nonculprit
TCFA in patients with ACS. Thus, a 1-time “look”
correlating FRS or demographics to presence of ahigh-risk plaque at another single time point may not
be enough.
Failure to establish a direct link between the FRS
and high-risk TCFA may not necessarily exclude
the possibility that clinical and angiographic char-
acteristics may have predictive accuracy in identi-
fying patients with untreated high-risk plaques
related to future adverse events. Clearly, more
research is needed to reach this conclusion.
Furthermore, the potential value of comprehensive
3-vessel imaging assessment (either invasive or
noninvasive) to assess plaque phenotype must be
linked to hard events before it can be recommended
for clinical use. Such comprehensive evaluation,
especially if it is invasive, has not led to a major
change in therapy at this time, and it may itself
trigger harmful complications.
To properly test predictability of clinical factors
for recurrent events, the design must include
sequential analyses of these factors, including low-
density lipoprotein cholesterol, high-density lipo-
protein cholesterol, blood pressure, glycosylated
hemoglobin, and physical activity. Considering the
beneﬁcial effects of aggressive statin therapy at the
plaque level (22), large delta changes will certainly
reduce the incidence of high-risk, nonculprit
TCFA, and prevent MACE. Conversely, small or
negative delta changes will increase incidence, and
probably predict MACE. Therefore, it is premature
to say that demographic factors are not associated
with clinically relevant, high-risk, nonobstructive
TCFA after ACS. Additional studies are urgently
needed to completely elucidate this issue.
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